AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22379918
Drug: FFP 6882+943
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FFP 6882+943 ml and crystalloids 6690+882 ml (1:1 ratio)
Trial: 22379918
Drug: FFP 7532+1196
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FFP 7532+1196 ml and crystalloids 3720+629 ml (2:1 ratio)
Trial: 7514771
Drug: Morphine or
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine or Heroin (specific dosage not mentioned)
Trial: 30928252
Drug: ICRS followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ICRS followed by CXL (concurrent)
Trial: 30928252
Drug: ICRS followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ICRS followed by CXL 3 months later (sequential)
Trial: 27798042
Drug: 6-month lifestyle
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month lifestyle intervention preceding infertility treatment
Trial: 17982321
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba (EGb 761, 300 mg/day)
Trial: 11073288
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral dose of imiquimod after fasting
Trial: 11073288
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral dose of imiquimod after a standardized, high fat meal
Trial: 11073288
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg subcutaneous dose of imiquimod
Trial: 1319110
Drug: Psyllium-enriched cereal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium-enriched cereal (114 g/d)
Trial: 2984980
Drug: Intranasally administered
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasally administered enviroxime
Trial: 3694540
Drug: Lorazepam (LZ)
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lorazepam (LZ) 1.5‐9.0 mg
Trial: 3694540
Drug: Meprobamate (MEP)
RxNorm normalized name: Meprobamate
DrugBank: Meprobamate (DB00371)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meprobamate (MEP) 600‐3600 mg
Trial: 30972904
Drug: Knutson's formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knutson's formula (povidone-iodine and sugar solution)
Trial: 30972904
Drug: Traditional topical
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional topical drugs
Trial: 25585890
Drug: Proton therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton therapy at a dose of 54 Gy in 30 fractions
Trial: 16505084
Drug: Sodium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium supplementation (620 mg table salt)
Trial: 16505084
Drug: Placebo (596
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (596 mg starch)
Trial: 12740158
Drug: HPS cream
RxNorm normalized name: capsaicin Topical Cream [Capzasin-HP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPS cream (Crystacide 1%) applied topically twice daily for 8 weeks
Trial: 12740158
Drug: Benzoyl peroxide
RxNorm normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide gel (PanOxyl gel 4%) applied topically twice daily for 8 weeks
Trial: 12903500
Drug: Oral furtulon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral furtulon therapy
Trial: 9313274
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three opioids (morphine, hydromorphone, sufentanil)
Trial: 7691253
Drug: Intensive weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intensive weekly chemotherapy (VAPEC-B) alone
Trial: 7691253
Drug: Intensive weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intensive weekly chemotherapy (VAPEC-B) with granulocyte colony-stimulating factor (G-CSF)
Trial: 7691253
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone or chemotherapy with G-CSF
Trial: 3536397
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg ISDN
Trial: 3536397
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg ISDN
Trial: 3536397
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg ISDN
Trial: 3536397
Drug: ISDN (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISDN (all doses)
Trial: 30318772
Drug: Cetuximab treatment
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab treatment in patients with FCGR2A H/H genotype (n=165, 28%)
Trial: 30318772
Drug: Cetuximab treatment
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab treatment in patients with FCGR2A R/- genotype (n=427, 72%)
Trial: 30318772
Drug: Cetuximab treatment
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab treatment in patients with FCGR2A H/R genotype
Trial: 30318772
Drug: Cetuximab treatment
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab treatment in patients with FCGR2A H/H + FCGR3A F/F genotype
Trial: 24652107
Drug: Varenicline 1
RxNorm normalized name: varenicline 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline 1 mg
Trial: 20034947
Drug: Triple dye
RxNorm normalized name: Triple Dye
DrugBank: Brilliant green cation (DB11279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple dye plus rubbing alcohol (isopropyl alcohol) twice daily
Trial: 16632346
Drug: Chemotherapy followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy followed by craniospinal RT (35 Gy in 21 fractions + boost of 20 Gy in 12 fractions)
Trial: 29995181
Drug: Education and
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education and motivation instructions in oral health and plaque control
Trial: 29231293
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) at Zusanli (ST 36) and Zhigou (TE 6), 30 min for each treatment, once a day for 5 days.
Trial: 29231293
Drug: Regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatment including intensive care, gastrointestinal decompression, fasting, blood capacity supplement, acid suppression treatment, internal environment maintenance, infection prevention, inhibition of pancreatic exocrine secretion.
Trial: 22078660
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (400mg daily) + Calcium (1200mg) + Vitamin D(3) (1000 IU)
Trial: 15308515
Drug: Infliximab (IFX)
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab (IFX) 3 mg/kg, three i.v. infusions on weeks 0, 2, and 6
Trial: 15308515
Drug: Methylprednisolone (MP)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (MP) 1 g, single i.v. infusion
Trial: 11468195
Drug: Cerivastatin (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerivastatin (0.15 mg/d for 3 days)
Trial: 2454980
Drug: Intralesional injection
RxNorm normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of 1 U/ml bleomycin sulfate
Trial: 2454980
Drug: Physiologic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic saline solution injection (control)
Trial: 27690687
Drug: Metformin 1000
RxNorm normalized name: metformin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1000 mg daily for 4 weeks, then 1500 mg daily for 8 weeks
Trial: 27690687
Drug: Megestrol 40
RxNorm normalized name: megestrol 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Megestrol 40 mg daily for 12 weeks
Trial: 25060103
Drug: Forgiveness therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forgiveness therapy (conducted once a week for 12 weeks)
Trial: 22057729
Drug: Micronized aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Micronized aspirin 500 mg
Trial: 22057729
Drug: Regular aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular aspirin 500 mg tablets
Trial: 12566892
Drug: Sildenafil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (200 mg)
Trial: 9640412
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (Genotropin) 0.25 IU/Kg/week (0.125 IU/kg/week for the first four weeks)
Trial: 9404870
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of creatine monohydrate per day for 5 consecutive days
Trial: 7059561
Drug: Chilean mixed
RxNorm normalized name: Chilean hazelnut oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chilean mixed diet at protein levels of 0.40, 0.55, and 0.70 g/kg body-weight per day
Trial: 7059561
Drug: Egg reference
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Egg reference diet providing 0.30, 0.45, and 0.60 g protein/kg per day
Trial: 28689602
Drug: Moisturizing gel
RxNorm normalized name: MOISTURIZING GEL
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moisturizing gel containing malva nut polysaccharide
Trial: 24030571
Drug: Pre-filled syringe
RxNorm normalized name: Eylea Pre-filled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-filled syringe formulation of canakinumab
Trial: 24030571
Drug: Reconstituted lyophilized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reconstituted lyophilized formulation of canakinumab
Trial: 17001467
Drug: Intravenous glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous glutamine (L-alanyl-L-glutamine 200mg/ml) for 20h at a rate of 0.125ml/kg/h
Trial: 9591517
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day tolcapone
Trial: 9591517
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day tolcapone
Trial: 788768
Drug: Antibiotic/corticosteroid combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic/corticosteroid combination
Trial: 2463912
Drug: N,N dimethylglycine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N,N dimethylglycine (DMG) 300 mg/day for the first 14 days, then 600 mg/day
Trial: 26674631
Drug: Average daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average daily moderate-to-vigorous physical activity (MVPA)
Trial: 22024518
Drug: TMC435 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC435 25 mg
Trial: 22024518
Drug: TMC435 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC435 75 mg
Trial: 22024518
Drug: TMC435 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC435 200 mg
Trial: 22024518
Drug: TMC435 (75,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC435 (75, 150, or 200 mg) in treatment-experienced patients
Trial: 22024518
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in treatment-experienced patients
Trial: 12779258
Drug: Fractionated radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractionated radiation therapy with a linear accelerator
Trial: 9071624
Drug: Topical bifonazole-urea
RxNorm normalized name: bifonazole / urea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical bifonazole-urea ointment alone
Trial: 9071624
Drug: Topical bifonazole-urea
RxNorm normalized name: bifonazole / urea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical bifonazole-urea ointment combined with oral griseofulvin 500 mg
Trial: 9071624
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral treatment)
Trial: 8219113
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily dose tobramycin (5 mg/kg per day) plus ceftriaxone (2 g/day) (C + T)
Trial: 8219113
Drug: Tobramycin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin (1.5 mg/kg, every 8 h) plus azlocillin (4 g, every 6 h) (A + T)
Trial: 2412051
Drug: Ketanserin (chronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (chronic treatment for 3 months)
Trial: 29477133
Drug: Ultrasound and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound and exercise therapy
Trial: 29477133
Drug: Placebo ultrasound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ultrasound and exercise therapy
Trial: 26654350
Drug: 375 mg
RxNorm normalized name: niacin 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg amoxicillin and 500 mg metronidazole three times per day for 7 days during the non-surgical treatment phase (T1)
Trial: 26654350
Drug: Antibiotics administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics administered during the surgical phase (T2)
Trial: 25277807
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional therapy (placebo group)
Trial: 18578178
Drug: Preparation at
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation at 15 minutes after cementation
Trial: 18578178
Drug: Preparation at
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation at 24 hours after cementation
Trial: 12431867
Drug: Therapeutic drug
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring (TDM) coupled with Bayesian forecasting (D(a))
Trial: 6355617
Drug: Furosemide (F)
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide (F) 40 mg daily for 3 days
Trial: 6355617
Drug: Captopril (C)
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril (C) 25 mg . 6 hr-1 with Furosemide (F)
Trial: 17900460
Drug: Aspirin prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin prescription
Trial: 15671918
Drug: ACEI or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI or ARB (angiotensin converting enzyme inhibitor or angiotensin receptor blocker)
Trial: 15671918
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or reference drug (beta-blocker or diuretic)
Trial: 12571548
Drug: Continuous Positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Positive Airway Pressure (CPAP) treatment for 1 week
Trial: 9506593
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy with combined streptokinase and tissue plasminogen activator
Trial: 3287912
Drug: Piroxicam 40
RxNorm normalized name: piroxicam 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 40 mg once daily for the first two days followed by 20 mg once daily for the remainder of the study (14 days, minimum 7 days, maximum 28 days)
Trial: 3287912
Drug: Aspirin 4
RxNorm normalized name: aspirin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 4 g per day for the duration of the study
Trial: 3287912
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg twice daily for two days followed by 250 mg in the morning and 500 mg in the evening thereafter
Trial: 3287912
Drug: Indomethacin 50
RxNorm normalized name: indomethacin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 50 mg three times per day for two days and 25 mg three times per day thereafter
Trial: 9287260
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.d. and clarithromycin 500 mg t.d.s. for two weeks (n = 27)
Trial: 9287260
Drug: De‐Nol 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: De‐Nol 240 mg b.d. for four weeks, metronidazole 400 mg t.d.s. and amoxicillin 500 mg t.d.s. for one week (n = 26)
Trial: 9287260
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.d. and amoxicillin 500 mg t.d.s. for two weeks (n = 26)
Trial: 9287260
Drug: Traditional 'triple'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional 'triple' therapy with bismuth and two antibiotics
Trial: 8320401
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy with dietary adherence support from dietitians
Trial: 3549320
Drug: Hydrochlorothiazide 50
RxNorm normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 50 mg once daily + Ibuprofen 400 mg t.i.d. for 4 weeks
Trial: 3549320
Drug: Hydrochlorothiazide 50
RxNorm normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 50 mg once daily + Diclofenac 25 mg t.i.d. for 4 weeks
Trial: 3549320
Drug: Hydrochlorothiazide 50
RxNorm normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 50 mg once daily + Sulindac 200 mg b.i.d. for 4 weeks
Trial: 20575298
Drug: Guo's Maqian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guo's Maqian decoction (200 ml, twice daily for 8 weeks, followed by Guokangning capsule (0.44 g per capsule, 2 capsules, three times daily for 4 weeks))
Trial: 20575298
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment including calcium supplementation and herb decoction
Trial: 11583826
Drug: Highly active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly active anti-retroviral therapy
Trial: 18669951
Drug: Other factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other factors (e.g., reduced body mass index, suboptimal nutrition, anti-retroviral drugs)
Trial: 12891224
Drug: Oxcarbazepine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine (30 to 46 mg/kg/day, given twice daily)
Trial: 10566573
Drug: Simvastatin 10
RxNorm normalized name: simvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 10 mg, titrated to 20 mg if necessary
Trial: 10566573
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg, titrated to 20 mg if necessary
Trial: 1809994
Drug: Lubor cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubor cream
Trial: 1809994
Drug: Ketonal cream
RxNorm normalized name: Ketonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketonal cream
Trial: 6340000
Drug: Fosfolip (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosfolip (calcium salt of phosphorylcholine chloride with pantethine) 3 capsules a day
Trial: 31260089
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) adjunctive therapy (400‐1200 mg once daily)
Trial: 31260089
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) adjunctive therapy
Trial: 31260089
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) monotherapy (1200‐1600 mg once daily)
Trial: 29579102
Drug: Pills rich
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pills rich in n‐3 PUFA
Trial: 27980393
Drug: Paracetamol (APAP)
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol (APAP) 2 g
Trial: 24172656
Drug: Physiotherapy-led exercise
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Physiotherapy-led exercise program (7 exercises daily for 12 weeks)
Trial: 24172656
Drug: Dexamethasone injection
RxNorm normalized name: dexamethasone Injection
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone injection followed by daily calf stretching
Trial: 20716080
Drug: Bupivacaine-tramadol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine-tramadol (1 mg x kg(‐1))
Trial: 17720116
Drug: Ultrasound-guided facet
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided facet joint injections